Patrick Dolezal
Stock Analyst at LifeSci Capital
(4.42)
# 1,099
Out of 4,349 analysts
173
Total ratings
43.4%
Success rate
13.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Patrick Dolezal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLGL Sol-Gel Technologies | Maintained: Buy | $184 | $75.28 | +144.42% | 2 | May 28, 2026 | |
| IBIO iBio, Inc. | Maintained: Buy | $5 | $1.93 | +159.07% | 11 | May 16, 2026 | |
| NGNE Neurogene | Maintained: Buy | $60 | $27.50 | +118.18% | 7 | May 16, 2026 | |
| OCS Oculis Holding AG | Maintained: Buy | $65 | $29.65 | +119.22% | 7 | May 16, 2026 | |
| MBX MBX Biosciences | Maintained: Buy | $75 → $91 | $31.90 | +185.27% | 3 | May 16, 2026 | |
| RCKT Rocket Pharmaceuticals | Rated: Buy | $12 | $3.02 | +297.35% | 44 | May 9, 2026 | |
| KOD Kodiak Sciences | Rated: Buy | $70 → $65 | $36.12 | +79.96% | 8 | May 9, 2026 | |
| SRZN Surrozen | Rated: Buy | $37 → $44 | $26.26 | +67.56% | 5 | May 9, 2026 | |
| GPCR Structure Therapeutics | Rated: Buy | $107 → $104 | $40.17 | +158.90% | 12 | May 9, 2026 | |
| TARS Tarsus Pharmaceuticals | Rated: Buy | $60 | $59.54 | n/a | 21 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $0.6869 | n/a | 25 | Nov 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $14 | $3.49 | n/a | 12 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 → $16 | $0.7989 | n/a | 5 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 | $31.70 | n/a | 1 | Dec 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27 → $25 | $5.23 | n/a | 2 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €10.00 → €25.00 | $4.55 | n/a | 8 | Jun 16, 2020 |
Sol-Gel Technologies
May 28, 2026
Maintained: Buy
Price Target: $184
Current: $75.28
Upside: +144.42%
iBio, Inc.
May 16, 2026
Maintained: Buy
Price Target: $5
Current: $1.93
Upside: +159.07%
Neurogene
May 16, 2026
Maintained: Buy
Price Target: $60
Current: $27.50
Upside: +118.18%
Oculis Holding AG
May 16, 2026
Maintained: Buy
Price Target: $65
Current: $29.65
Upside: +119.22%
MBX Biosciences
May 16, 2026
Maintained: Buy
Price Target: $75 → $91
Current: $31.90
Upside: +185.27%
Rocket Pharmaceuticals
May 9, 2026
Rated: Buy
Price Target: $12
Current: $3.02
Upside: +297.35%
Kodiak Sciences
May 9, 2026
Rated: Buy
Price Target: $70 → $65
Current: $36.12
Upside: +79.96%
Surrozen
May 9, 2026
Rated: Buy
Price Target: $37 → $44
Current: $26.26
Upside: +67.56%
Structure Therapeutics
May 9, 2026
Rated: Buy
Price Target: $107 → $104
Current: $40.17
Upside: +158.90%
Tarsus Pharmaceuticals
Dec 11, 2023
Rated: Buy
Price Target: $60
Current: $59.54
Upside: n/a
Nov 11, 2023
Maintained: Buy
Price Target: $6
Current: $0.6869
Upside: n/a
Aug 10, 2023
Rated: Buy
Price Target: $14
Current: $3.49
Upside: n/a
Mar 9, 2023
Maintained: Buy
Price Target: $17 → $16
Current: $0.7989
Upside: n/a
Dec 11, 2022
Maintained: Buy
Price Target: $39
Current: $31.70
Upside: n/a
Mar 8, 2021
Maintained: Buy
Price Target: $27 → $25
Current: $5.23
Upside: n/a
Jun 16, 2020
Reiterated: Buy
Price Target: €10.00 → €25.00
Current: $4.55
Upside: n/a